Our initial focus is improving patients’ quality of life following major surgery by 1) accelerating postoperative return of gastrointestinal (GI) function to shorten their length of stay in the hospital and 2) prevention of post-surgical adhesions to reduce need for additional surgeries.

Additionally, we plan to pursue follow-on indications to address a myriad of health conditions and complications associated with chronic disruption of the intestinal mucosal barrier.

Our most advanced candidate, LB1148, is a Phase 3-ready oral protease inhibitor drug with the potential ability to protect intestinal integrity during and after surgery, representing a pipeline within a drug given the wide array of health complications that intestinal enzyme damage can cause.